NeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears

$NTHIPress releaseAug 10, 2026, 10:34 AM ETRead the release

NeOnc Technologies is scheduled to present topline Phase 2a data for NEO100 on August 12, evaluating the treatment in patients with recurrent IDH1-mutant high-grade glioma. CEO Amir Heshmatpour has invested over $500,000 in open-market purchases, with total insider buying approaching $1 million over the past year.

Key figures

Drug Name: NEO100
Phase Of Trial: Phase 2a
Insider buying ceo: >$500,000
Insider buying total: approaching $1,000,000

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.